Patents by Inventor Daniele Piomelli

Daniele Piomelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10363237
    Abstract: Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 30, 2019
    Assignees: The Regents of the University of California, Universita Degli Studi Di Urbino “Carlo Bo”, Universita Degli Studi Di Parma
    Inventors: Daniele Piomelli, Giorgio Tarzia, Marco Mor, Andrea Duranti, Andrea Tontini
  • Publication number: 20190177313
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.
    Type: Application
    Filed: May 16, 2017
    Publication date: June 13, 2019
    Inventors: Daniele Piomelli, Rita Scarpelli, Marco Migliore
  • Patent number: 10226452
    Abstract: The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 12, 2019
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Tecnologia
    Inventors: Daniele Piomelli, Chiara Pagliuca, Daniela Pizzirani, Anders Bach, Natalia Realini, Marco De Vivo
  • Patent number: 10213416
    Abstract: The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides substituted benzoxazolone derivatives for use in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 26, 2019
    Assignees: The Regents of the University of Chicago, Fondazione Istituto Italiano di Technologia
    Inventors: Daniele Piomelli, Daniela Pizzirani, Anders Bach, Rita Scarpelli, Laurin Melzig, Marco Mor
  • Publication number: 20180194722
    Abstract: Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 12, 2018
    Inventors: Daniele PIOMELLI, Tiziano Bandiera, Rita Scarpelli
  • Patent number: 9908848
    Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: March 6, 2018
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Tecnologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di Parma
    Inventors: Daniele Piomelli, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Tiziano Bandiera, Angelo Mario Reggiani
  • Patent number: 9828352
    Abstract: The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar?, R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 28, 2017
    Assignees: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Giovanni Bottegoni, Alessio De Simone, Gian Filippo Ruda, Andrea Cavalli, Tiziano Bandiera, Daniele Piomelli
  • Patent number: 9828338
    Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 28, 2017
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Technologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di Parma
    Inventors: Daniele Piomelli, Tiziano Bandiera, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Stefano Ponzano, Chiara Pagliuca, Angelo Mario Reggiani, Marco Mor, Giorgio Tarzia
  • Patent number: 9822068
    Abstract: Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: November 21, 2017
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Technologia
    Inventors: Daniele Piomelli, Tiziano Bandiera, Rita Scarpelli
  • Patent number: 9745255
    Abstract: The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). The present invention also sets forth methods for inhibiting FAAH as well as methods for treating conditions such as, but not limited to, pain, inflammation, immune disorders, dermatitis, mucositis, the over reactivity of peripheral sensory neurons, neurodermatitis, and an overactive bladder. Accordingly, the invention also provides compounds, methods, and pharmaceutical compositions for treating conditions in which the selective inhibition of peripheral FAAH (as opposed to CNS FAAH) would be of benefit.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: August 29, 2017
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Technologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di Parma
    Inventors: Daniele Piomelli, Guillermo Moreno-Sanz, Tiziano Bandiera, Marco Mor, Giorgio Tarzia
  • Publication number: 20170182009
    Abstract: The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides substituted benzoxazolone derivatives for use in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 29, 2017
    Inventors: Daniele PIOMELLI, Daniela PIZZIRANI, Anders BACH, Rita SCARPELLI, Laurin MELZIG, Marco MOR
  • Publication number: 20170182010
    Abstract: The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 29, 2017
    Inventors: Daniele PIOMELLI, Chiara PAGLIUCA, Daniela PIZZIRANI, Anders BACH, Natalia REALINI, Marco DE VIVO
  • Patent number: 9630914
    Abstract: Multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2) having a specific carbamate moiety on the meta or ortho position of the A ring of a substituted biphenyl core and having an halogen in the ortho position of the B ring of the biphenyl core. Also concerns the therapeutical application of the multitarget inhibitors, in particular, in the prevention and treatment of cancer.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: April 25, 2017
    Assignees: Fondazione Istituto Italiano Di Tecnologia, The Regents of the University of California, Alma Mater Studiorum—Universita' Di Bologna
    Inventors: Marco De Vivo, Rita Scarpelli, Andrea Cavalli, Marco Migliore, Daniele Piomelli, Damien Habrant, Angelo Favia
  • Publication number: 20170088510
    Abstract: Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.
    Type: Application
    Filed: October 6, 2016
    Publication date: March 30, 2017
    Inventors: Daniele PIOMELLI, Tiziano BANDIERA, Rita SCARPELLI
  • Publication number: 20160256432
    Abstract: Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.
    Type: Application
    Filed: March 16, 2016
    Publication date: September 8, 2016
    Inventors: Daniele Piomelli, Giorgio Tarzia, Marco Mor, Andrea Duranti, Andrea Tontini
  • Patent number: 9428465
    Abstract: The present invention concerns, in a first aspect, compounds of Formula I as defined herein, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds. The present invention also relates to compounds of Formula I for use as acid ceramidase inhibitors, and in the treatment of cancer and other disorders in which modulation of the levels of ceramide is clinically relevant.
    Type: Grant
    Filed: May 27, 2013
    Date of Patent: August 30, 2016
    Assignee: Fondazione Istituto Italiano Di Technologia
    Inventors: Daniele Piomelli, Natalia Realini, Marco Mor, Chiara Pagliuca, Daniela Pizzirani, Rita Scarpelli, Tiziano Bandiera
  • Publication number: 20160235707
    Abstract: The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.
    Type: Application
    Filed: April 25, 2016
    Publication date: August 18, 2016
    Inventors: Daniele Piomelli, Tiziano Bandiera, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Stefano Ponzano
  • Publication number: 20160194296
    Abstract: The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar?, R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.
    Type: Application
    Filed: July 10, 2014
    Publication date: July 7, 2016
    Inventors: Giovanni BOTTEGONI, Alessio DE SIMONE, Gian Filippo RUDA, Andrea CAVALLI, Tiziano BANDIERA, Daniele PIOMELLI
  • Patent number: 9353075
    Abstract: The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: May 31, 2016
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano Di Technologia, Universita Degli Studi Di Parma, Universita Degli Studi Di Urbino “Carlo Bo”
    Inventors: Daniele Piomelli, Tiziano Bandiera, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Stefano Ponzano
  • Patent number: 9321743
    Abstract: Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: April 26, 2016
    Assignees: The Regents of the University of California, Universita Degli Studi Di Parma, Universita Degli Studi Di Urbino “Carlo Bo”
    Inventors: Daniele Piomelli, Giorgio Tarzia, Marco Mor, Andrea Duranti, Andrea Tontini